Direct exposure of human alpha-1-proteinase inhibitor to the gas-phase smoke from one cigarette results in an initial rapid loss of elastase inhibitory capacity, the amount of which is dependent upon the age of the smoke. This short-term inactivation is not seen when the protein is exposed to aqueous extracts of cigarette smoke (as had been done in the past). Both exposure regimens result in a slow inactivation occurring over several days. We suggest that the short-term inactivation may be due to a peroxynitrate (or a similar reactive species) that is formed from radicals in the gas phase but is unstable in aqueous solution.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0006-291x(84)80086-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing the efficacy of Alpha-Proteinase inhibitor (human) augmentation therapy for Alpha-Antitrypsin deficiency - Related emphysema: Challenges and opportunities.
Heliyon
June 2024
Ross Pierce MD, LLC, 1330 West Avenue Unit 506, Miami Beach, FL 33139, USA.
Clinical benefit of Alpha-Proteinase Inhibitor (Human) (A-PI) products for Alpha-antitrypsin deficiency (AATD) is uncertain, based on a systematic review of observational studies and randomized controlled trials (RCTs) in AATD of Alpha-Proteinase Inhibitor (Human) (A-PI) products. At the recommended dose, A-PI products raise its serum concentration but do not normalize levels. Observational studies suggest A-PI might modestly slow progression of airflow limitation in patients with intermediate airflow obstruction, a finding not confirmed by three placebo-controlled RCTs of limited power, which showed non-significant rates of forced expiratory volume in 1Â s (FEV) change favoring placebo.
View Article and Find Full Text PDFCase report: Self-administration of alpha-1 antitrypsin therapy: a report of two cases.
Front Pharmacol
November 2023
Hospital Pharmacy Department, Hospital Universitario Costa del Sol, Marbella, Spain.
Intravenous augmentation therapy with human alpha-1 proteinase inhibitor for the management of respiratory disease is recommended for people with alpha-1 antitrypsin deficiency (AATD) who are nonsmokers or former smokers. Augmentation therapy usually requires weekly administration at the hospital or clinic and poses an additional burden for patients due to interference with daily life, including work and social activities. Self-administration is a useful alternative to overcome this limitation, but there is a lack of published information on clinical outcomes.
View Article and Find Full Text PDFEvaluation of body weight-based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency.
Pulm Pharmacol Ther
December 2023
Takeda Development Center Americas, Inc., Cambridge, MA, United States.
Introduction: The recommended standard dose for α-proteinase inhibitor (A1PI) augmentation therapy is 60 mg/kg once-weekly (QW) intravenous (IV) infusions that aim to maintain systemic A1PI levels >11 μM, the biochemical efficacy threshold, in patients with α-antitrypsin deficiency (AATD). However, this standard dose may not be optimal for all patients. Body weight-based dosing, alternative dosing regimens, and treatment interruption periods were evaluated using population pharmacokinetic (PopPK) modeling and simulations.
View Article and Find Full Text PDFThe universal proteinase inhibitor α2-macroglobulin (α₂-MG) exhibiting antiviral and immunomodulatory activities, is considered as an important participant in the infectious process. The activity of α₂-MG in the new coronavirus infection and post-covid syndrome (long COVID) has not been studied yet. We examined 85 patients diagnosed with community-acquired bilateral polysegmental pneumonia developed under conditions of a new coronavirus infection SARS-CoV-2.
View Article and Find Full Text PDFAugmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.
Am J Respir Crit Care Med
November 2023
Department of Medicine, Irish Center for Genetic Lung Disease, Royal College of Surgeons in Ireland, Dublin, Ireland.
Article Synopsis
- Intravenous plasma-purified alpha-1 antitrypsin (IV-AAT) has been used since 1987 to treat alpha-1 antitrypsin deficiency (AATD), showing benefits in lung density preservation but limited effects on forced expiratory volume (FEV).
- A study of 615 severe AATD patients across Ireland, Switzerland, and Austria found that while IV-AAT improves survival rates, it does not significantly affect FEV decline, particularly in patients with certain lung profiles.
- The research identifies two AATD phenotypes and suggests that older patients in a plateau phase may not benefit from FEV-focused trials, indicating the need to reconsider how clinical trials are designed and who
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!